Sevirumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CMV |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| ChemSpider | none |
| (verify) | |
Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
References
- ↑ Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI; et al. (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
- ↑ ClinicalTrials.gov
This article is issued from Wikipedia - version of the 11/19/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.